Skip to main content

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.

Publication ,  Journal Article
Gay, CL; Mayo, AJ; Mfalila, CK; Chu, H; Barry, AC; Kuruc, JD; McGee, KS; Kerkau, M; Sebastian, J; Fiscus, SA; Margolis, DM; Hicks, CB ...
Published in: AIDS
April 24, 2011

OBJECTIVE: Characterize responses to non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral treatment (ART) initiated during acute HIV infection (AHI). DESIGN: This was a prospective, single-arm evaluation of once-daily, co-formulated emtricitabine/tenofovir/efavirenz initiated during AHI. METHODS: The primary endpoint is the proportion of responders with HIV RNA less than 200 copies/ml by week 24. We examined time to viral suppression and CD8 cell activation in relation to baseline participant characteristics. We compared time to viral suppression and viral dynamics using linear mixed-effects models between acutely infected participants and chronically infected controls. RESULTS: Between January 2005 and May 2009, 61 AHI participants were enrolled. Of participants whose enrollment date allowed 24 and 48 weeks of follow-up, 47 of 51 (92%) achieved viral suppression to less than 200 copies/ml by week 24, and 35 of 41 (85.4%) to less than 50 copies/ml by week 48. The median time from ART initiation to suppression below 50 copies/ml was 93 days (range 14-337). Higher HIV RNA levels at ART initiation (P = 0.02), but not time from estimated date of infection to ART initiation (P = 0.86), were associated with longer time to viral suppression. The median baseline frequency of activated CD8+CD38+HLA-DR+ T cells was 67% (range 40-95), and was not significantly associated with longer time to viral load suppression (P = 0.15). Viremia declined to less than 50 copies/ml more rapidly in AHI than chronically infected participants. Mixed-model analysis demonstrated similar phase I HIV RNA decay rates between acute and chronically infected participants, and more rapid viral decline in acutely infected participants in phase II. CONCLUSION: Once-daily emtricitabine/tenofovir/efavirenz initiated during AHI achieves rapid and sustained HIV suppression during this highly infectious period.

Duke Scholars

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

April 24, 2011

Volume

25

Issue

7

Start / End Page

941 / 949

Location

England

Related Subject Headings

  • Young Adult
  • Virology
  • Viral Load
  • Treatment Outcome
  • Tenofovir
  • Reverse Transcriptase Inhibitors
  • RNA, Viral
  • Prospective Studies
  • Organophosphonates
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gay, C. L., Mayo, A. J., Mfalila, C. K., Chu, H., Barry, A. C., Kuruc, J. D., … Duke-UNC Acute HIV Infection Consortium, . (2011). Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS, 25(7), 941–949. https://doi.org/10.1097/QAD.0b013e3283463c07
Gay, Cynthia L., Ashley J. Mayo, Chelu K. Mfalila, Haitao Chu, Anna C. Barry, JoAnn D. Kuruc, Kara S. McGee, et al. “Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.AIDS 25, no. 7 (April 24, 2011): 941–49. https://doi.org/10.1097/QAD.0b013e3283463c07.
Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, et al. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24;25(7):941–9.
Gay, Cynthia L., et al. “Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.AIDS, vol. 25, no. 7, Apr. 2011, pp. 941–49. Pubmed, doi:10.1097/QAD.0b013e3283463c07.
Gay CL, Mayo AJ, Mfalila CK, Chu H, Barry AC, Kuruc JD, McGee KS, Kerkau M, Sebastian J, Fiscus SA, Margolis DM, Hicks CB, Ferrari G, Eron JJ, Duke-UNC Acute HIV Infection Consortium. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011 Apr 24;25(7):941–949.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

April 24, 2011

Volume

25

Issue

7

Start / End Page

941 / 949

Location

England

Related Subject Headings

  • Young Adult
  • Virology
  • Viral Load
  • Treatment Outcome
  • Tenofovir
  • Reverse Transcriptase Inhibitors
  • RNA, Viral
  • Prospective Studies
  • Organophosphonates
  • Middle Aged